{"id":51289,"date":"2025-07-31T07:08:55","date_gmt":"2025-07-31T11:08:55","guid":{"rendered":"https:\/\/stockmarketwatch.com\/stock-market-news\/global-markets-react-to-key-earnings-economic-data-and-geopolitical-shifts\/51289\/"},"modified":"2025-07-31T07:08:55","modified_gmt":"2025-07-31T11:08:55","slug":"global-markets-react-to-key-earnings-economic-data-and-geopolitical-shifts","status":"publish","type":"post","link":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/global-markets-react-to-key-earnings-economic-data-and-geopolitical-shifts\/51289\/","title":{"rendered":"Global Markets React to Key Earnings, Economic Data, and Geopolitical Shifts"},"content":{"rendered":"<h2>Key Takeaways<\/h2>\n<ul>\n<li><strong>The Japanese Yen (<a href=\"\/stock\/USDJPY\">USDJPY<\/a>) has fallen to 150 against the U.S. Dollar for the first time since April 2<\/strong>, signaling continued weakness in the Japanese currency.<\/li>\n<li><strong>Eli Lilly&#39;s (<a href=\"\/stock\/LLY\">LLY<\/a>) Mounjaro demonstrated significant heart-health benefits<\/strong> in a head-to-head trial against Trulicity, showing an 8% lower rate of major heart events and a 16% reduction in overall death rate. Despite these positive results, Eli Lilly shares dropped 4.9%.<\/li>\n<li><strong>KKR (<a href=\"\/stock\/KKR\">KKR<\/a>) exceeded Q2 earnings estimates<\/strong>, reporting adjusted EPS of <strong>$1.18<\/strong> against an estimate of <strong>$1.14<\/strong>, and declaring a regular dividend of <strong>$0.185\/share<\/strong>.<\/li>\n<li><strong>CVS Health (<a href=\"\/stock\/CVS\">CVS<\/a>) reported strong Q2 revenue of $98.92 billion<\/strong>, surpassing estimates of $94.50 billion, and raised its full-year adjusted EPS outlook.<\/li>\n<li><strong>Ukraine&#39;s parliament approved a bill to reinstate anti-corruption authorities<\/strong>, a move aimed at addressing a significant political crisis and international pressure.<\/li>\n<\/ul>\n<p>Global financial markets are reacting to a flurry of corporate earnings, significant pharmaceutical trial results, and ongoing geopolitical developments. The Japanese Yen has notably depreciated, while several major companies have released their second-quarter financial reports.<\/p>\n<p>The <strong>Japanese Yen<\/strong> has reached <strong>150 against the U.S. Dollar<\/strong>, a level not seen since April 2, indicating persistent pressure on the currency.<\/p>\n<p><strong>Eli Lilly and Company&#39;s<\/strong> (<a href=\"\/stock\/LLY\">LLY<\/a>) diabetes drug, <strong>Mounjaro<\/strong>, showed promising results in its SURPASS-CVOT Phase 3 trial, demonstrating cardiovascular protection. The trial revealed an <strong>8% lower rate of major adverse cardiovascular events (MACE-3)<\/strong> and a <strong>16% lower rate of all-cause death<\/strong> compared to Trulicity (<a href=\"\/stock\/LLY\">LLY<\/a>). Mounjaro also achieved greater reductions in A1C and weight. Despite these positive clinical outcomes, Eli Lilly&#39;s shares experienced a 4.9% decline.<\/p>\n<p>Private equity firm <strong>KKR<\/strong> (<a href=\"\/stock\/KKR\">KKR<\/a>) announced a strong second quarter, with <strong>adjusted EPS of $1.18<\/strong>, exceeding the estimated <strong>$1.14<\/strong>. The firm&#39;s fee-related earnings reached <strong>$887 million<\/strong>, and its assets under management (AUM) stood at <strong>$686 billion<\/strong>, surpassing the estimated <strong>$680.51 billion<\/strong>. KKR also declared a regular dividend of <strong>$0.185 per share<\/strong> for Q2 and remains &quot;highly constructive&quot; entering the second half of the year, having raised <strong>$6.5 billion<\/strong> to invest in asset-backed finance.<\/p>\n<p><strong>CVS Health<\/strong> (<a href=\"\/stock\/CVS\">CVS<\/a>) reported robust second-quarter results, with total revenue of <strong>$98.92 billion<\/strong>, significantly higher than the estimated <strong>$94.50 billion<\/strong>. The company&#39;s adjusted EPS came in at <strong>$1.81<\/strong>, exceeding the IBES estimate of <strong>$1.46<\/strong>. CVS Health also raised its full-year adjusted EPS outlook to a range of <strong>$6.30 to $6.40<\/strong>, up from the previous estimate of <strong>$6.12<\/strong>. The medical benefit ratio increased to <strong>89.9%<\/strong>, and the company recorded <strong>$833 million in litigation charges<\/strong> during the quarter.<\/p>\n<p>Luxury sports car manufacturer <strong>Ferrari<\/strong> (<a href=\"\/stock\/RACE\">RACE<\/a>) reported its Q2 2025 earnings, with <strong>net profit at EUR425 million<\/strong> (estimated EUR426 million) and <strong>revenue at EUR1.79 billion<\/strong> (estimated EUR1.82 billion). Diluted EPS was <strong>EUR2.38<\/strong> (estimated EUR2.40). The company&#39;s EBIT was <strong>EUR552 million<\/strong> (estimated EUR546 million) and EBITDA was <strong>EUR709 million<\/strong> (estimated EUR707.8 million). Deliveries for the quarter totaled <strong>3,494 units<\/strong> (estimated 3,515).<\/p>\n<p><strong>Xerox<\/strong> (<a href=\"\/stock\/XRX\">XRX<\/a>) announced its Q2 results, with <strong>revenue of $1,576 million<\/strong> and a gross margin of <strong>28.6%<\/strong>. The company reported an adjusted operating income of <strong>$59 million<\/strong>, but an adjusted EPS of <strong>-$0.64<\/strong> and GAAP EPS of <strong>-$0.87<\/strong>.<\/p>\n<p><strong>Biogen<\/strong> (<a href=\"\/stock\/BIIB\">BIIB<\/a>) also released its Q2 earnings, reporting <strong>EPS of $4.33<\/strong> and adjusted EPS of <strong>$5.47<\/strong>, significantly exceeding the estimate of <strong>$3.86<\/strong>. Revenue for the quarter was <strong>$2,600 million<\/strong>, higher than the estimated <strong>$2,323 million<\/strong>. Biogen provided a full-year adjusted EPS outlook of <strong>$15.50-$16.00<\/strong>.<\/p>\n<p>In other news, <strong>Klarna<\/strong>, the buy now, pay later lender, is reportedly preparing to revive its planned <strong>$15 billion New York stock market flotation<\/strong> in the autumn, after postponing it in April due to tariff-induced market turmoil.<\/p>\n<p><a href=\"https:\/\/stockmarketwatch.com\/metal\/silver-price.aspx\" data-internallinksmanager029f6b8e52c=\"5\" title=\"silver price today\">Silver<\/a> prices experienced a collapse yesterday following a <em>risk-off attitude<\/em> in most precious metals markets post-FOMC. Analysts suggest keeping an eye on the <strong>$35.50\/oz<\/strong> level for support, with a potential flush out to <strong>$32\/oz<\/strong> if that level fails to hold.<\/p>\n<p>The <strong>European Union<\/strong> confirmed ongoing talks regarding a <strong>tariff exemption for wine and spirits<\/strong>. The EU Commission also stated its preparedness to collect demand from EU firms to purchase additional U.S. Liquefied Natural Gas.<\/p>\n<p>Finally, <strong>Citigroup<\/strong> has raised its target price for <strong>Microsoft<\/strong> (<a href=\"\/stock\/MSFT\">MSFT<\/a>) to <strong>$680 from $613<\/strong> and for <strong>Meta<\/strong> (<a href=\"\/stock\/META\">META<\/a>) to <strong>$915 from $803<\/strong>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Key Takeaways The Japanese Yen (USDJPY) has fallen to 150 against the U.S. Dollar for the first time since April [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":50383,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"rank_math_schema_Article":[],"rank_math_focus_keyword":[],"rank_math_description":[],"financial_data_references":[],"stock_symbols_mentioned":[],"footnotes":""},"categories":[5012],"tags":[5395,337,6725,474,6761,814,7013,1375,7436,1798,7446,2029,7447,3856,7448,7449,5042,7450,5378],"class_list":["post-51289","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-breaking-news","tag-aum","tag-lly","tag-usdjpy","tag-xrx","tag-eli-lilly","tag-biib","tag-biogen","tag-kkr","tag-eu-tariffs","tag-cvs","tag-mounjaro","tag-silver","tag-ferrari","tag-race","tag-cvs-health","tag-xerox","tag-ukraine","tag-klarna","tag-yen"],"_links":{"self":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts\/51289","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/comments?post=51289"}],"version-history":[{"count":0,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts\/51289\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/media\/50383"}],"wp:attachment":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/media?parent=51289"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/categories?post=51289"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/tags?post=51289"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}